HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Suberoylanilide hydroxamic acid (SAHA), a pan HDAC inhibitor, has been approved by the Food and Drug Administration (FDA) to treat cutaneous T cell lymphoma (CTCL).